Kruchinina M V
Institute of Cytology and Genetics-SB RAS, Russia
Title: The lipid metabolites of blood serum and erythrocytes: the opportunities for diagnosis of colorectal cancer
Biography
Kruchinina M V has completed her Doctor of Medicine degree at Institute of Internal Medicine SB RAS, Novosibirsk, Russia. From 2009, she is a Leading Researcher at Research Institute of Internal and Preventive Medicine–Branch of Federal State Budget Scientific Institution of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia. She is the author of more than 120 publications, including one monograph, five teaching aids and eight patents. Her areas of scientific interests are metabolomics, microcirculation, rheology, membrane disorders in oncopathology, endocrinological, cerebrovascular, cardiovascular pathology and diagnosis of diffuse liver pathology.
Abstract
The aim of the work was to evaluate lipid metabolites of blood serum (BS) and red blood cells (RBCs) as potential biomarkers for the diagnosis of colorectal cancer (CRC). BS, RBCs from 95 patients (56+8 years old) with colorectal adenocarcinoma (early stages I-II, n=44; late stages III-IV, n=51) and 28 healthy controls were analyzed by FT mass spectrometry, GC/MS system triple quad Agilent 7000B (USA). The list one of the BS lipid metabolites - amines of fatty acids (FA) (palmitic amide, erucamide, oleamide), saturated FA (C14:0, 16:0, 18:0), polyunsaturated FA (C20:3, 20:4), lysophosphatidylcholines (m>2) (C18:2, 20:2, 20:4, 20:6, 22:6) allowed us to obtain the high level of AUC 0.98 (sensitivity 0,97, specificity 0,99) when comparing early stage CRC patients with controls. Panel two including the following lipids of BS - palmitic amide, erucamide, oleamide, myristic, palmitic, stearic acids, lysophosphatidic acids, LPC(16:0)- showed good opportunities for distinguishing the CRC patients from healthy controls (AUC 0,95 (0,8, 0,96). The combination of the lipids - phosphatidylcholine, phosphatidylserine, lysophosphatidylcholines (18:0, 18:1, 18:2, 20:4, 20:6, 22:6), palmitic acid – differentiated the late stages from the early ones (AUC 0,91 (0,80, 0,92). Differentiating FA of RBCs membranes were polyunsaturated (C20:0, C20:2, C20:3, C20:4, C22:4, C22:5, C22:6), the levels of which were significantly higher in CRC patients, and saturated and monounsaturated (C 12-17:0, C16:1, C 18:1, C18:2), prevailing in healthy controls. The observed shifts correlated with the CRC stages. The lipid metabolites of blood serum and erythrocytes should be considered as the promising biomarkers for CRC diagnosis
Min-kyung Yeo
Chungnam National University, South Korea
Title: The polarity regulatory PAR complex expression in colorectal adenocarcinoma: correlation with clinical characteristic and prognosis
Biography
Min-kyung Yeo has completed her Medical degree at Chungnam National University, Daejeon, South Korea in 2007 and PhD in 2015 at the same university. She is working as an Assistant Professor in the Department of Pathology at Chungnam National University Hospital, Daejeon, South Korea.
Abstract
Partitioning defective (Par) proteins regulate cell polarity and differentiation. Par3, Par6β, and protein kinase Cζ (PKCζ), which are PAR complex members, have been shown to be associated with oncogenesis and progression. Herein, we report the expression pattern and clinical relevance of Par3, Par6β, and PKCζ in colorectal adenocarcinoma (CRAC). A total of 393 primary CRACs, 41 primary-metastatic CRAC pairs, 41 adenomas with low-grade dysplasia, and 41 non-tumor colorectal tissue samples were examined by immunohistochemistry and western blot assays for Par3, Par6β, and PKCζ protein expressions. The association Par3, Par6β, and PKCζ expressions and clinicopathological factors, including patient survival, was evaluated. Primary CRACs and adenomas demonstrated higher levels of Par3, Par6β, and PKCζ than in non-tumor colorectal epithelia. The expressions of Par3, Par6β, and PKCζ were higher in primary CRACs as compared to adenomas or in metastatic CRACs. Among primary CRACs, decreased Par3 expression was found to correlate with a high proliferation rate and poor histological differentiation, decreased PKCζ expression was correlated with pathological TNM stage (I-II versus III-IV) and lymph node metastasis, and decreased Par6β and PKCζ expressions were correlated with shortened overall survivals. In metastatic CRACs, decreased PKCζ expression was correlated with a shortened metastasis-free survival. While increased Par3, Par6β, and PKCζ expressions were implicated in tumorigenesis, decreased expressions of Par3, Par6β, and PKCζ were found to be associated with worse clinicopathological factors in CRAC. In particular, the results of our study suggest that PKCζ down-expression is an independent poor prognostic and metastatic factor for CRAC.